{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:46:19Z","timestamp":1791161179989,"version":"4.1.0"},"reference-count":354,"publisher":"Elsevier BV","issue":"6","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.smim.2013.10.008","type":"journal-article","created":{"date-parts":[[2013,11,23]],"date-time":"2013-11-23T04:46:04Z","timestamp":1385181964000},"page":"469-484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":496,"title":["Treating inflammation by blocking interleukin-1 in humans"],"prefix":"10.1016","volume":"25","author":[{"given":"Charles A.","family":"Dinarello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos W.M.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.smim.2013.10.008_bib0005","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1056\/NEJMoa0809568","article-title":"An autoinflammatory disease due to homozygous deletion of the IL1RN locus","volume":"360","author":"Reddy","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.smim.2013.10.008_bib0010","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1056\/NEJMoa0807865","article-title":"An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist","volume":"360","author":"Aksentijevich","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.smim.2013.10.008_bib0015","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1084\/jem.20082481","article-title":"In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes","volume":"206","author":"Lachmann","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.smim.2013.10.008_bib0020","doi-asserted-by":"crossref","first-page":"20684","DOI":"10.1073\/pnas.1116848108","article-title":"Sterile inflammation of endothelial cell-derived apoptotic bodies is mediated by interleukin-1alpha","volume":"108","author":"Berda-Haddad","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.smim.2013.10.008_bib0025","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrrheum.2009.229","article-title":"The role of microparticles in the pathogenesis of rheumatic diseases","volume":"6","author":"Beyer","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib0030","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.4049\/jimmunol.1102048","article-title":"IL-1\u03b1 and IL-1\u03b2 recruit different myeloid cells and promote different stages of sterile inflammation","volume":"187","author":"Rider","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.smim.2013.10.008_bib0035","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1073\/pnas.0915018107","article-title":"Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation","volume":"107","author":"Cohen","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.smim.2013.10.008_bib0040","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.4049\/jimmunol.139.6.1902","article-title":"Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro","volume":"139","author":"Dinarello","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/j.smim.2013.10.008_bib0045","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1074-7613(04)00046-9","article-title":"NALP3 forms an IL-1beta processing inflammasome with increased activity in Muckle\u2013Wells auto-inflammatory disorder","volume":"20","author":"Agostini","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.smim.2013.10.008_bib0050","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev.immunol.021908.132715","article-title":"The inflammasomes: guardians of the body","volume":"27","author":"Martinon","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.smim.2013.10.008_bib0055","doi-asserted-by":"crossref","first-page":"10889","DOI":"10.1074\/jbc.R110.135491","article-title":"Genetic and molecular basis of inflammasome-mediated disease","volume":"286","author":"Hoffman","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.smim.2013.10.008_bib0060","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev.immunol.25.022106.141627","article-title":"Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease","volume":"27","author":"Masters","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.smim.2013.10.008_bib0065","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/art.23437","article-title":"The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis","volume":"58","author":"Gattorno","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib0070","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1002\/art.22842","article-title":"Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations","volume":"56","author":"Gattorno","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib0075","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJMoa055137","article-title":"Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition","volume":"355","author":"Goldbach-Mansky","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.smim.2013.10.008_bib0080","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade","volume":"201","author":"Pascual","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.smim.2013.10.008_bib0085","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/rheumatology\/keq074","article-title":"Dysregulation of P2X7 receptor-inflammasome axis in SAPHO syndrome: successful treatment with anakinra","volume":"49","author":"Colina","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.smim.2013.10.008_bib0090","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cell.2010.02.043","article-title":"Anti-inflammatory agents: present and future","volume":"140","author":"Dinarello","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.smim.2013.10.008_bib0095","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1002\/art.27663","article-title":"How interleukin-1beta induces gouty arthritis","volume":"62","author":"Dinarello","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib0100","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.smim.2013.10.008_bib0105","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1161\/CIRCULATIONAHA.107.740233","article-title":"Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction","volume":"117","author":"Abbate","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.smim.2013.10.008_bib0110","first-page":"343","article-title":"Effects of therapy with interleukin-1 receptor antagonist on pulmonary cytokine expression following hemorrhage and resuscitation","volume":"13","author":"Abraham","year":"1994","journal-title":"Lymphokine Cytokine Res"},{"key":"10.1016\/j.smim.2013.10.008_bib0115","first-page":"59","article-title":"IL-1 regulates in vivo C-X-C chemokine induction and neutrophil sequestration following endotoxemia","volume":"8","author":"Calkins","year":"2002","journal-title":"J Endotoxin Res"},{"key":"10.1016\/j.smim.2013.10.008_bib0120","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1432-2277.2008.00651.x","article-title":"Administration of interleukin-1 receptor antagonist ameliorates renal ischemia-reperfusion injury","volume":"21","author":"Rusai","year":"2008","journal-title":"Transpl Int"},{"key":"10.1016\/j.smim.2013.10.008_bib0125","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.1523\/JNEUROSCI.21-15-05528.2001","article-title":"Role of IL-1alpha and IL-1beta in ischemic brain damage","volume":"21","author":"Boutin","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.smim.2013.10.008_bib0130","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/jnnp.2004.054882","article-title":"A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients","volume":"76","author":"Emsley","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.smim.2013.10.008_bib0135","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF03261881","article-title":"Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events","volume":"26","author":"Abbate","year":"2012","journal-title":"BioDrugs"},{"key":"10.1016\/j.smim.2013.10.008_bib0140","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/eurjhf\/hfq017","article-title":"Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse","volume":"12","author":"Abbate","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.smim.2013.10.008_bib0145","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.amjcard.2013.01.287","article-title":"Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]","volume":"111","author":"Abbate","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.smim.2013.10.008_bib0150","doi-asserted-by":"crossref","first-page":"e33438","DOI":"10.1371\/journal.pone.0033438","article-title":"Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure","volume":"7","author":"Van Tassell","year":"2012","journal-title":"PLOS One"},{"key":"10.1016\/j.smim.2013.10.008_bib0155","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.107.731877","article-title":"Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis","volume":"117","author":"Ikonomidis","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.smim.2013.10.008_bib0160","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/00003246-199907000-00018","article-title":"Tumor necrosis factor-\u03b1 and interleukin-1\u03b2 synergistically depress human myocardial function","volume":"27","author":"Cain","year":"1999","journal-title":"Crit Care Med"},{"key":"10.1016\/j.smim.2013.10.008_bib0165","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1073\/pnas.041611398","article-title":"Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta","volume":"98","author":"Pomerantz","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.smim.2013.10.008_bib0170","article-title":"Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure with preserved ejection fraction","author":"Van Tassell","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.smim.2013.10.008_bib0175","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/nrendo.2009.271","article-title":"Blockade of interleukin 1 in type 1 diabetes mellitus","volume":"6","author":"Mandrup-Poulsen","year":"2010","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.smim.2013.10.008_bib0180","first-page":"A50","article-title":"IL-1ra delays the spontaenous autoimmune diabetes in the BB rat","volume":"22","author":"Dayer-Metroz","year":"1992","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.smim.2013.10.008_bib0185","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1399-5448.2011.00761.x","article-title":"Preliminary studies related to anti-interleukin-1beta therapy in children with newly diagnosed type 1 diabetes","volume":"12","author":"Sumpter","year":"2011","journal-title":"Pediatr Diabetes"},{"issue":"Suppl. 10","key":"10.1016\/j.smim.2013.10.008_bib0190","first-page":"2055","article-title":"Evaluation of safety and preliminary efficacy of canakinumab in children with systemic onset juvenile idiopaththic artritis","volume":"60","author":"Ruperto","year":"2009","journal-title":"Arthr Rheumat."},{"key":"10.1016\/j.smim.2013.10.008_bib0195","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/art.34409","article-title":"Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes","volume":"64","author":"Sibley","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.smim.2013.10.008_bib0200","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.smim.2011.07.009","article-title":"A historical view from thirty eventful years of immunotherapy in autoimmune diabetes","volume":"23","author":"Bach","year":"2012","journal-title":"Semin Immunol"},{"key":"10.1016\/j.smim.2013.10.008_bib0205","first-page":"1296","article-title":"Factors predictive of cyclosporine-induced nephrotoxicity: the role of cyclosporine blood levels","volume":"22","author":"Bach","year":"1990","journal-title":"Transplant Proc"},{"key":"10.1016\/j.smim.2013.10.008_bib0210","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1056\/NEJMoa012864","article-title":"Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus","volume":"346","author":"Herold","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.smim.2013.10.008_bib0215","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.smim.2013.10.008_bib0220","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1210\/jc.2010-2992","article-title":"Treatment with anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study","volume":"96","author":"van Asseldonk","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.smim.2013.10.008_bib0225","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(13)60023-9","article-title":"Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials","volume":"381","author":"Moran","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.smim.2013.10.008_bib0230","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1172\/JCI200215318","article-title":"Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets","volume":"110","author":"Maedler","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.smim.2013.10.008_bib0235","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/ni.1935","article-title":"Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes","volume":"11","author":"Masters","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.smim.2013.10.008_bib0240","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa065213","article-title":"Interleukin-1-receptor antagonist in type 2 diabetes mellitus","volume":"356","author":"Larsen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.smim.2013.10.008_bib0245","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/dc09-0533","article-title":"Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes","volume":"32","author":"Larsen","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.smim.2013.10.008_bib0250","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.2337\/dc11-2219","article-title":"Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes","volume":"35","author":"Cavelti-Weder","year":"2012","journal-title":"Diabetes Care"},{"issue":"Suppl. 1A","key":"10.1016\/j.smim.2013.10.008_bib0255","article-title":"IL-1beta antibody (canakinumab) improves insulin secretion rates in subjects with impaired glucose tolerance and type 2 diabetes","volume":"60","author":"Rissanen","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.smim.2013.10.008_bib0260","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.2337\/dc12-1835","article-title":"Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes","volume":"36","author":"Sloan-Lancaster","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.smim.2013.10.008_bib0265","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.2337\/dc11-1196","article-title":"Inhibition of IL-1beta improves fatigue in type 2 diabetes","volume":"34","author":"Cavelti-Weder","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.smim.2013.10.008_bib0270","doi-asserted-by":"crossref","first-page":"e30123","DOI":"10.1371\/journal.pone.0030123","article-title":"Interleukin-1 inhibition and fatigue in primary Sjogren's syndrome\u2014a double blind, randomised clinical trial","volume":"7","author":"Norheim","year":"2012","journal-title":"PLOS One"},{"key":"10.1016\/j.smim.2013.10.008_bib0275","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.cmet.2010.11.011","article-title":"The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity","volume":"12","author":"Stienstra","year":"2011","journal-title":"Cell Metab"},{"key":"10.1016\/j.smim.2013.10.008_bib0280","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.atherosclerosis.2006.11.026","article-title":"Differential role and tissue specificity of interleukin-1alpha gene expression in atherogenesis and lipid metabolism","volume":"195","author":"Kamari","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.smim.2013.10.008_bib0285","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.smim.2013.10.008_bib0290","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","article-title":"Inflammation in atherosclerosis: from pathophysiology to practice","volume":"54","author":"Libby","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.smim.2013.10.008_bib0295","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","article-title":"Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"162","author":"Ridker","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.smim.2013.10.008_bib0300","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1161\/CIRCULATIONAHA.112.122556","article-title":"Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial","volume":"126","author":"Ridker","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.smim.2013.10.008_bib0305","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3899\/jrheum.090074","article-title":"Anakinra for rheumatoid arthritis: a systematic review","volume":"36","author":"Mertens","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib0310","first-page":"32","article-title":"Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice, Outcome in 60 patients with severe rheumatoid arthritis","volume":"59","author":"Botsios","year":"2007","journal-title":"Reumatismo"},{"key":"10.1016\/j.smim.2013.10.008_bib0315","first-page":"1103","article-title":"Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis, extension of a 24-week randomized, placebo-controlled trial","volume":"31","author":"Bresnihan","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib0320","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P","article-title":"A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores","volume":"43","author":"Jiang","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 1","key":"10.1016\/j.smim.2013.10.008_bib0325","first-page":"169","article-title":"Treatment with anakinra reduces the rate of joint destruction and shows accelerated benefit in the secon 6 months of treatment for patients with rheumatoid arthritis","volume":"40","author":"Genant","year":"2001","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.smim.2013.10.008_bib0330","first-page":"171","article-title":"Durability and rapidity of response for rheumatoid arthritis patients receiving therapy with anakinra","volume":"60","author":"Miller","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib0335","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1073\/pnas.1011774108","article-title":"Blockade of TNF-alpha rapidly inhibits pain responses in the central nervous system","volume":"108","author":"Hess","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.smim.2013.10.008_bib0340","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2474-12-153","article-title":"Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study","volume":"12","author":"Alten","year":"2011","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.smim.2013.10.008_bib0345","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/art.24694","article-title":"Case of anakinra as a steroid-sparing agent for gout inflammation","volume":"61","author":"Gratton","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib0350","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1136\/ard.2007.073759","article-title":"Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra","volume":"66","author":"McGonagle","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib0355","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/art.23119","article-title":"Successful treatment of resistant pseudogout with anakinra","volume":"58","author":"McGonagle","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib0360","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/RHU.0b013e3181be2423","article-title":"IL-1 inhibition with anakinra in a patient with refractory gout","volume":"15","author":"Singh","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib0365","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1002\/art.27600","article-title":"Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study","volume":"62","author":"So","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib0370","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","article-title":"A pilot study of IL-1 inhibition by anakinra in acute gout","volume":"9","author":"So","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.smim.2013.10.008_bib0375","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/ard.2009.108936","article-title":"The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study","volume":"68","author":"Terkeltaub","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib0380","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrrheum.2009.236","article-title":"Update on gout: new therapeutic strategies and options","volume":"6","author":"Terkeltaub","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib0385","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jbspin.2009.01.001","article-title":"Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure","volume":"76","author":"Announ","year":"2009","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.smim.2013.10.008_bib0390","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar3297","article-title":"Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study","volume":"13","author":"Schlesinger","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.smim.2013.10.008_bib0395","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/ard.2010.144063","article-title":"Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study","volume":"70","author":"Schlesinger","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib0400","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1002\/art.27667","article-title":"Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1beta production via the ASC\/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis","volume":"62","author":"Joosten","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib0405","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1002\/art.25006","article-title":"Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta","volume":"60","author":"Joosten","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib0410","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/ard.2008.094284","article-title":"Erosive osteoarthritis of the hand: clinical experience with anakinra","volume":"68","author":"Bacconnier","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib0415","first-page":"1317","article-title":"Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study","volume":"32","author":"Chevalier","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib0420","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/art.24096","article-title":"Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study","volume":"61","author":"Chevalier","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib0425","doi-asserted-by":"crossref","first-page":"R125","DOI":"10.1186\/ar3430","article-title":"A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL 1R1) in patients with osteoarthritis of the knee","volume":"13","author":"Cohen","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.smim.2013.10.008_bib0430","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1365-2141.2009.07733.x","article-title":"Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy","volume":"146","author":"Chae","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.smim.2013.10.008_bib0435","doi-asserted-by":"crossref","first-page":"9982","DOI":"10.1073\/pnas.0602081103","article-title":"The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production","volume":"103","author":"Chae","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.smim.2013.10.008_bib0440","doi-asserted-by":"crossref","first-page":"43","DOI":"10.5144\/0256-4947.2012.43","article-title":"A retrospective review of autoinflammatory diseases in Saudi children at a rheumatology clinic","volume":"32","author":"Alenazi","year":"2012","journal-title":"Ann Saudi Med"},{"key":"10.1016\/j.smim.2013.10.008_bib0445","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1093\/ndt\/gfr528","article-title":"Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure","volume":"27","author":"Stankovic Stojanovic","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.smim.2013.10.008_bib0450","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10067-009-1279-8","article-title":"Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behcet's disease","volume":"29","author":"Bilginer","year":"2010","journal-title":"Clin Rheumatol."},{"key":"10.1016\/j.smim.2013.10.008_bib0455","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/ndt\/gfn646","article-title":"Successful treatment of familial Mediterranean fever with anakinra and outcome after renal transplantation","volume":"24","author":"Moser","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.smim.2013.10.008_bib0460","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.semarthrit.2010.11.003","article-title":"Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature","volume":"41","author":"Meinzer","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib0465","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00431-007-0547-3","article-title":"The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever","volume":"167","author":"Calligaris","year":"2008","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.smim.2013.10.008_bib0470","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1136\/ard.2010.146878","article-title":"The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis","volume":"70","author":"Mitroulis","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib0475","article-title":"MEFV mutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease","author":"Stoffels","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib0480","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/BOR.0b013e328349c3b1","article-title":"Hyper-IgD syndrome or mevalonate kinase deficiency","volume":"23","author":"Stoffels","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib0485","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jmb.2005.11.074","article-title":"Topological frustration and the folding of interleukin-1 beta","volume":"357","author":"Gosavi","year":"2006","journal-title":"J Mol Biol"},{"key":"10.1016\/j.smim.2013.10.008_bib0490","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1136\/ard.2011.149922","article-title":"On-demand anakinra treatment is effective in mevalonate kinase deficiency","volume":"70","author":"Bodar","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib0495","first-page":"260","article-title":"Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model","volume":"63","author":"Bodar","year":"2005","journal-title":"Neth J Med"},{"key":"10.1016\/j.smim.2013.10.008_bib0500","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s10545-006-0408-7","article-title":"Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis","volume":"29","author":"Cailliez","year":"2006","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib0505","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1651-2227.2010.01974.x","article-title":"Hyperimmunoglobulinemia D and periodic fever syndrome in children, review on therapy with biological drugs and case report","volume":"100","author":"Korppi","year":"2011","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.smim.2013.10.008_bib0510","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00296-009-1322-8","article-title":"Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome","volume":"32","author":"Shendi","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.smim.2013.10.008_bib0515","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/MD.0b013e318190cfb7","article-title":"Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome","volume":"87","author":"van der Hilst","year":"2008","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.smim.2013.10.008_bib0520","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jaci.2006.12.649","article-title":"Monocytes from familial cold autoinflammatory syndrome patients are activated by mild hypothermia","volume":"119","author":"Rosengren","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.smim.2013.10.008_bib0525","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.4049\/jimmunol.175.4.2630","article-title":"IL-converting enzyme\/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients","volume":"175","author":"Stack","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.smim.2013.10.008_bib0530","doi-asserted-by":"crossref","first-page":"9789","DOI":"10.1073\/pnas.1000779107","article-title":"Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1beta secretion","volume":"107","author":"Tassi","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.smim.2013.10.008_bib0535","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1007\/s00296-011-2019-3","article-title":"\u201cMutation negative\u201d familial cold autoinflammatory syndrome (FCAS) in an 8-year-old boy: clinical course and functional studies","volume":"32","author":"Hedrich","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.smim.2013.10.008_bib0540","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/art.23687","article-title":"Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies","volume":"58","author":"Hoffman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib0545","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab in the cryopyrin-associated periodic syndrome","volume":"360","author":"Lachmann","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.smim.2013.10.008_bib0550","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1212\/WNL.0b013e3181d9ed69","article-title":"Neurologic manifestations of the cryopyrin-associated periodic syndrome","volume":"74","author":"Kitley","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.smim.2013.10.008_bib0555","doi-asserted-by":"crossref","first-page":"R202","DOI":"10.1186\/ar3535","article-title":"Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study","volume":"13","author":"Kone-Paut","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.smim.2013.10.008_bib0560","doi-asserted-by":"crossref","first-page":"R34","DOI":"10.1186\/ar3266","article-title":"Canakinumab (ACZ885, a fully human IgG1 anti-IL-1beta mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)","volume":"13","author":"Kuemmerle-Deschner","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.smim.2013.10.008_bib0565","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1136\/ard.2011.152728","article-title":"Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes","volume":"70","author":"Kuemmerle-Deschner","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib0570","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/0194599811402296","article-title":"Cryopyrin-associated periodic syndromes: otolaryngologic and audiologic manifestations","volume":"145","author":"Ahmadi","year":"2011","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.smim.2013.10.008_bib0575","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1055\/s-0029-1239527","article-title":"Improvement of sensoneurinal hearing loss in a patient with Muckle\u2013Wells syndrome treated with anakinra","volume":"222","author":"Klein","year":"2011","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.smim.2013.10.008_bib0580","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0092-8674(00)80721-7","article-title":"Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes","volume":"97","author":"McDermott","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.smim.2013.10.008_bib0585","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0952-7915(00)00124-2","article-title":"TNFRSF1A mutations and autoinflammatory syndromes","volume":"12","author":"Galon","year":"2000","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.smim.2013.10.008_bib0590","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1002\/art.23475","article-title":"Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome","volume":"58","author":"Gattorno","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib0595","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.amjmed.2004.02.039","article-title":"Beneficial response to interleukin-1 receptor antagonist in TRAPS","volume":"117","author":"Simon","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.smim.2013.10.008_bib0600","first-page":"357","article-title":"Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy","volume":"35","author":"Sacre","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib0605","first-page":"802","article-title":"Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment","volume":"28","author":"Cantarini","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib0610","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/art.24174","article-title":"Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease?","volume":"60","author":"Picco","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib0615","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/j.jccase.2011.07.003","article-title":"A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis","volume":"4","author":"Scott","year":"2011","journal-title":"J Cardiol Cases"},{"key":"10.1016\/j.smim.2013.10.008_bib0620","doi-asserted-by":"crossref","first-page":"R196","DOI":"10.1186\/ar3526","article-title":"NLRP3 E311K mutation in a large family with Muckle\u2013Wells syndrome\u2014description of a heterogeneous phenotype and response to treatment","volume":"13","author":"Kuemmerle-Deschner","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.smim.2013.10.008_bib0625","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/rheumatology\/ken030","article-title":"Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA)","volume":"47","author":"Ohlsson","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.smim.2013.10.008_bib0630","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib0635","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1136\/ard.2009.108068","article-title":"IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease","volume":"69","author":"Naumann","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib0640","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France","volume":"67","author":"Lequerre","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib0645","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.semarthrit.2007.04.002","article-title":"Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature","volume":"37","author":"Kotter","year":"2007","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib0650","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/ard.2006.066381","article-title":"Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial","volume":"66","author":"Kalliolias","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib0655","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/art.21061","article-title":"Rapid responses to anakinra in patients with refractory adult-onset Still's disease","volume":"52","author":"Fitzgerald","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib0660","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1517\/14712598.2010.532785","article-title":"The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis","volume":"10","author":"Swart","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.smim.2013.10.008_bib0665","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/art.33342","article-title":"A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features","volume":"64","author":"Ruperto","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib0670","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/ard.2005.045245","article-title":"Beneficial reponse to anakinra and thalidomide in Schnitzler's syndrome","volume":"65","author":"De Koning","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib0675","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/art.21101","article-title":"Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al","volume":"52","author":"Martinez-Taboada","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib0680","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1093\/rheumatology\/kem244","article-title":"Comment on: Schnitzlers syndrome\u2014exacerbation after anti-TNF treatment","volume":"46","author":"de Koning","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.smim.2013.10.008_bib0685","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jaci.2007.09.021","article-title":"IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission","volume":"121","author":"Ryan","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.smim.2013.10.008_bib0690","first-page":"271","article-title":"Schnitzler syndrome: diagnostics and treatment","volume":"24","author":"Szturz","year":"2011","journal-title":"Klin Onkol"},{"key":"10.1016\/j.smim.2013.10.008_bib0695","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.jaci.2011.05.023","article-title":"Successful canakinumab treatment identifies IL-1beta as a pivotal mediator in Schnitzler syndrome","volume":"128","author":"de Koning","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.smim.2013.10.008_bib0700","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jbspin.2007.07.010","article-title":"Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: a case report","volume":"75","author":"Furlan","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.smim.2013.10.008_bib0705","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","article-title":"Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study","volume":"71","author":"Gul","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib0710","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jamaophthalmol.2013.195","article-title":"Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial","volume":"131","author":"Amparo","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.smim.2013.10.008_bib0715","article-title":"Interleukin-1 blockade in refractory giant cell arteritis","author":"Ly","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.smim.2013.10.008_bib0720","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000343221","article-title":"Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report","volume":"226","author":"van der Zee","year":"2013","journal-title":"Dermatology"},{"key":"10.1016\/j.smim.2013.10.008_bib0725","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","article-title":"Elevated levels of tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-alpha and IL-1beta","volume":"164","author":"van der Zee","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.smim.2013.10.008_bib0730","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1001\/jamadermatol.2013.5377","article-title":"Successful Treatment of Severe Hidradenitis Suppurativa With Anakinra","volume":"149","author":"Zarchi","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.smim.2013.10.008_bib0735","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/157488412803305821","article-title":"An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases","volume":"7","author":"Pazyar","year":"2012","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.smim.2013.10.008_bib0740","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jaad.2010.12.025","article-title":"Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)\u2014a new autoinflammatory syndrome distinct from PAPA syndrome","volume":"66","author":"Braun-Falco","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.smim.2013.10.008_bib0745","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/archdermatol.2010.328","article-title":"Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review","volume":"146","author":"Hsiao","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.smim.2013.10.008_bib0750","article-title":"Pyoderma gangrenosum and concomitant hidradenitis suppurativa\u2014rapid response to canakinumab (anti-IL-1beta)","author":"Jaeger","year":"2013","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.smim.2013.10.008_bib0755","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11926-011-0165-y","article-title":"Current status of understanding the pathogenesis and management of patients with NOMID\/CINCA","volume":"13","author":"Goldbach-Mansky","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.smim.2013.10.008_bib0760","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jpeds.2010.02.040","article-title":"Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra","volume":"157","author":"Lepore","year":"2011","journal-title":"J Pediatr"},{"key":"10.1016\/j.smim.2013.10.008_bib0765","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1546-0096-8-9","article-title":"Effect of anakinra on arthropathy in CINCA\/NOMID syndrome","volume":"8","author":"Miyamae","year":"2011","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.smim.2013.10.008_bib0770","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.25057","article-title":"Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease\/chronic infantile neurologic, cutaneous, articular syndrome","volume":"62","author":"Neven","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib0775","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000331580","article-title":"Muckle\u2013Wells syndrome effectively treated with canakinumab: is the recommended dosing schedule mandatory?","volume":"223","author":"Mueller","year":"2011","journal-title":"Dermatology"},{"key":"10.1016\/j.smim.2013.10.008_bib0780","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.4049\/jimmunol.1002275","article-title":"IL-1beta is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease","volume":"186","author":"Pathak","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.smim.2013.10.008_bib0785","first-page":"249","article-title":"Association of interleukin-1 gene polymorphisms with sudden sensorineural hearing loss and Meniere's disease","volume":"38","author":"Furuta","year":"2011","journal-title":"Int J Immunopharmacol"},{"key":"10.1016\/j.smim.2013.10.008_bib0790","doi-asserted-by":"crossref","first-page":"e5293","DOI":"10.1371\/journal.pone.0005293","article-title":"Alternate splicing of interleukin-1 receptor type II (IL1R2) in vitro correlates with clinical glucocorticoid responsiveness in patients with AIED","volume":"4","author":"Vambutas","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.smim.2013.10.008_bib0795","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jbspin.2010.04.018","article-title":"Anakinra efficacy in a Caucasian patient with renal AA amyloidosis secondary to cryopyrin-associated periodic syndrome","volume":"77","author":"Ait-Abdesselam","year":"2011","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.smim.2013.10.008_bib0800","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10067-009-1279-8","article-title":"Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behcet's disease","volume":"29","author":"Bilginer","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib0805","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/art.30149","article-title":"Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome","volume":"63","author":"Kuemmerle-Deschner","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib0810","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.ajkd.2006.10.026","article-title":"Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleukin 1 receptor antagonist","volume":"49","author":"Thornton","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib0815","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1212\/01.wnl.0000263217.36439.da","article-title":"Inflammatory markers and the risk of Alzheimer disease: the Framingham Study","volume":"68","author":"Tan","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.smim.2013.10.008_bib0820","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00246-013-0663-y","article-title":"Successful treatment of idiopathic recurrent pericarditis with interleukin-1 receptor antagonist (Anakinra)","volume":"34","author":"Camacho-Lovillo","year":"2013","journal-title":"Pediatric Cardiol"},{"key":"10.1016\/j.smim.2013.10.008_bib0825","article-title":"Efficacy of an interleukin-1beta receptor antagonist (anakinra) in idiopathic recurrent pericarditis","author":"Scardapane","year":"2012","journal-title":"Pediatric cardiology"},{"key":"10.1016\/j.smim.2013.10.008_bib0830","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijcard.2012.05.086","article-title":"Successful treatment of adult patients with idiopathic recurrent pericarditis with an interleukin-1 receptor antagonist (anakinra)","volume":"160","author":"Vassilopoulos","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.smim.2013.10.008_bib0835","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10741-012-9335-x","article-title":"Pericardial syndromes: an update after the ESC guidelines 2004","volume":"18","author":"Seferovic","year":"2013","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.smim.2013.10.008_bib0840","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/IAI.69.3.1847-1855.2001","article-title":"Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology","volume":"69","author":"Mohan","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.smim.2013.10.008_bib0845","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/ard.2009.111500","article-title":"Demyelinating events in rheumatoid arthritis after drug exposures","volume":"69","author":"Bernatsky","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib0850","doi-asserted-by":"crossref","first-page":"13046","DOI":"10.1073\/pnas.1002396107","article-title":"Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis","volume":"107","author":"Meissner","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.smim.2013.10.008_bib0855","first-page":"302","article-title":"Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra)","volume":"67","author":"Bodar","year":"2009","journal-title":"Neth J Med"},{"key":"10.1016\/j.smim.2013.10.008_bib0860","doi-asserted-by":"crossref","first-page":"12741","DOI":"10.1073\/pnas.1007946107","article-title":"Blocking IL-1beta to slow down progression of ALS?","volume":"107","author":"van der Meer","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.smim.2013.10.008_bib0865","first-page":"S21","article-title":"Interleukin-1 and its relevance in patients treated with hemodialysis","volume":"33","author":"Dinarello","year":"1988","journal-title":"Kidney Int"},{"key":"10.1016\/j.smim.2013.10.008_bib0870","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1681\/ASN.2010070760","article-title":"IL-1beta receptor antagonist reduces inflammation in hemodialysis patients","volume":"22","author":"Hung","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.smim.2013.10.008_bib0875","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0889-8588(05)70115-5","article-title":"The role of interleukin-1 beta in the pathogenesis of multiple myeloma","volume":"13","author":"Lust","year":"1999","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.smim.2013.10.008_bib0880","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4065\/84.2.114","article-title":"Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component","volume":"84","author":"Lust","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.smim.2013.10.008_bib0885","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/ard.2005.048371","article-title":"Safety of extended treatment with anakinra in patients with rheumatoid arthritis","volume":"65","author":"Fleischmann","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib0890","first-page":"95","article-title":"Anakinra for the inflammatory complications of chronic granulomatous disease","volume":"69","author":"van de Veerdonk","year":"2011","journal-title":"Neth J Med"},{"key":"10.1016\/j.smim.2013.10.008_bib0895","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s00296-010-1429-y","article-title":"Pneumonia in a patient with familial Mediterranean fever successfully treated with anakinra-case report and review","volume":"32","author":"Hennig","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.smim.2013.10.008_bib0900","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","article-title":"The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement","volume":"36","author":"Solovic","year":"2011","journal-title":"J. Eur Respir"},{"key":"10.1016\/j.smim.2013.10.008_bib0905","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/art.10870","article-title":"Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial","volume":"48","author":"Fleischmann","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib0910","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","article-title":"Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist","volume":"41","author":"Bresnihan","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib0915","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/RHU.0b013e31812e00a1","article-title":"Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra)","volume":"13","author":"Settas","year":"2007","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib0920","first-page":"553","article-title":"Clinical experience of QuantiFERON((R))-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan","volume":"164","author":"Chiu","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.smim.2013.10.008_bib0925","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jaad.2010.12.025","article-title":"Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)-a new autoinflammatory syndrome distinct from PAPA syndrome","volume":"66","author":"Braun-Falco","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.smim.2013.10.008_bib0930","article-title":"Overproduction of interleukin-17 in a family with hidradenitis suppurativa: response to anakinra therapy","author":"Netea","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.smim.2013.10.008_bib0935","first-page":"1265","article-title":"Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review","volume":"146","author":"Hsiao","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.smim.2013.10.008_bib0940","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095","article-title":"Biological basis for interleukin-1 in disease","volume":"87","author":"Dinarello","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.smim.2013.10.008_bib0945","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4049\/jimmunol.156.1.389","article-title":"IL-1 beta does not cause neutrophil degranulation but does lead to IL-6, IL-8, and nitrite\/nitrate release when used in patients with cancer","volume":"156","author":"Ogilvie","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.smim.2013.10.008_bib0950","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/1043-4666(92)90078-6","article-title":"Pharmacokinetics, saftey, and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans","volume":"4","author":"Granowitz","year":"1992","journal-title":"Cytokine"},{"key":"10.1016\/j.smim.2013.10.008_bib0955","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/rheumatology\/41.9.972","article-title":"Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage","volume":"41","author":"Abramson","year":"2002","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl. 2","key":"10.1016\/j.smim.2013.10.008_bib0960","first-page":"ii22","article-title":"Clinical and radiological effects of anakinra in patients with rheumatoid arthritis","volume":"42","author":"Bresnihan","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.smim.2013.10.008_bib0965","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1590\/S1516-31802010000500013","article-title":"Biologics for rheumatoid arthritis: an overview of Cochrane reviews","volume":"128","author":"Singh","year":"2010","journal-title":"Sao Paulo Med J"},{"key":"10.1016\/j.smim.2013.10.008_bib0970","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s10067-010-1654-5","article-title":"Secondary failure to treatment with recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis","volume":"30","author":"Bao","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"Suppl. 9","key":"10.1016\/j.smim.2013.10.008_bib0975","first-page":"S289","article-title":"Anakinra reduces the rate of joint destruction after 1 year of treatment in a randomized controlled cohort of patients with rheumatoid arthritis","volume":"43","author":"Bresnihan","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib0980","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/rheumatology\/40.1.62","article-title":"The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis","volume":"40","author":"Cunnane","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.smim.2013.10.008_bib0985","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1592\/phco.31.1.39","article-title":"Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach","volume":"31","author":"Devine","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.smim.2013.10.008_bib0990","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3899\/jrheum.100089","article-title":"Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis","volume":"38","author":"Wang","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib0995","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1185\/03007995.2011.608655","article-title":"A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis","volume":"27","author":"Turkstra","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.smim.2013.10.008_bib1000","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1093\/rheumatology\/kem072","article-title":"The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons","volume":"46","author":"Nixon","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.smim.2013.10.008_bib1005","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/rheumatology\/keh152","article-title":"Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy","volume":"43","author":"Cohen","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.smim.2013.10.008_bib1010","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.rdc.2004.01.005","article-title":"The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis","volume":"30","author":"Cohen","year":"2004","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.smim.2013.10.008_bib1015","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/BF02850127","article-title":"Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis","volume":"23","author":"Kavanaugh","year":"2006","journal-title":"Adv Ther"},{"key":"10.1016\/j.smim.2013.10.008_bib1020","first-page":"225","article-title":"Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis","volume":"30","author":"Cohen","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1025","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1136\/ard.2003.016014","article-title":"A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate","volume":"63","author":"Cohen","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib1030","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1186\/ar3228","article-title":"Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy\u2014a single centre, open-label study","volume":"13","author":"Pontifex","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.smim.2013.10.008_bib1035","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s10067-010-1504-5","article-title":"An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX)","volume":"29","author":"Jung","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-0031-1275398","article-title":"Clinical benefits of intra-articular anakinra for persistent knee effusion","volume":"24","author":"Brown","year":"2011","journal-title":"J Knee Surg"},{"key":"10.1016\/j.smim.2013.10.008_bib1045","first-page":"877","article-title":"Clinical benefits of intra-articular anakinra for arthrofibrosis","volume":"33","author":"Brown","year":"2011","journal-title":"Orthopedics"},{"key":"10.1016\/j.smim.2013.10.008_bib1050","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.joca.2011.12.009","article-title":"Effects of intraarticular IL1-Ra for acute anterior cruciate ligament knee injury: a randomized controlled pilot trial (NCT00332254)","volume":"20","author":"Kraus","year":"2012","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.smim.2013.10.008_bib1055","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.lpm.2009.01.012","article-title":"Indications of anakinra","volume":"38","author":"Chauffier","year":"2009","journal-title":"Presse Med"},{"key":"10.1016\/j.smim.2013.10.008_bib1060","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00296-009-0981-9","article-title":"Relapsing polychondritis: new therapeutic strategies with biological agents","volume":"30","author":"Buonuomo","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.smim.2013.10.008_bib1065","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/rheumatology\/kel041","article-title":"Refractory relapsing polychondritis: rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra)","volume":"45","author":"Vounotrypidis","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.smim.2013.10.008_bib1070","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s00296-011-2020-x","article-title":"Adult-onset Still's disease and chronic recurrent multifocal osteomyelitis: a hitherto undescribed manifestation of autoinflammation","volume":"32","author":"Rech","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.smim.2013.10.008_bib1075","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/rheumatology\/keq122","article-title":"Biologic therapy in refractory chronic non-bacterial osteomyelitis of childhood","volume":"49","author":"Eleftheriou","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.smim.2013.10.008_bib1080","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/ard.2004.023176","article-title":"Open label trial of anakinra in active ankylosing spondylitis over 24 weeks","volume":"64","author":"Haibel","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib1085","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/rheumatology\/kem302","article-title":"Sustained response to anakinra in ankylosing spondylitis","volume":"47","author":"Bennett","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.smim.2013.10.008_bib1090","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/ard.2004.020800","article-title":"Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study","volume":"63","author":"Tan","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib1095","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nrrheum.2010.78","article-title":"Epidemiology: Gout\u2013bad for the heart as well as the joint","volume":"6","author":"So","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/RHU.0b013e31827d8790","article-title":"Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis","volume":"19","author":"Cronstein","year":"2013","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1105","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/acr.21989","article-title":"Treatment of acute gouty arthritis in complex hospitalized patients with anakinra","volume":"65","author":"Ghosh","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.smim.2013.10.008_bib1110","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/RHU.0b013e31826149a2","article-title":"Interleukin 1beta blockade improves signs and symptoms of chronic calcium pyrophosphate crystal arthritis resistant to treatment","volume":"18","author":"Diamantopoulos","year":"2012","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1115","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jbspin.2012.01.010","article-title":"Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis","volume":"79","author":"Molto","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.smim.2013.10.008_bib1120","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jbspin.2012.07.018","article-title":"Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature","volume":"80","author":"Ottaviani","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.smim.2013.10.008_bib1125","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/rheumatology\/keq358","article-title":"First observation of the efficacy of IL-1ra to treat tophaceous gout of the lumbar spine","volume":"50","author":"Funck-Brentano","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.smim.2013.10.008_bib1130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2013.06.004","article-title":"Interleukin-1 blockade in refractory giant cell arteritis","author":"Ly","year":"2013","journal-title":"Joint Bone Spine."},{"key":"10.1016\/j.smim.2013.10.008_bib1135","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1136\/annrheumdis-2012-202738","article-title":"Interleukin-1 receptor antagonist in refractory haemochromatosis-related arthritis of the hands","volume":"72","author":"Latourte","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib1140","first-page":"489","article-title":"Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient","volume":"66","author":"Mitroulis","year":"2008","journal-title":"Neth J Med"},{"key":"10.1016\/j.smim.2013.10.008_bib1145","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/TP.0b013e3181d84cc3","article-title":"Transmission of familial Mediterranean fever mutation after bone marrow transplantation and successful treatment with anakinra","volume":"90","author":"Petropoulou","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.smim.2013.10.008_bib1150","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12016-013-8358-y","article-title":"IL-1beta biological treatment of familial Mediterranean fever","volume":"45","author":"Soriano","year":"2013","journal-title":"Clinical Rev Allergy Immunol"},{"key":"10.1016\/j.smim.2013.10.008_bib1155","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/MAJ.0b013e318277083b","article-title":"Efficacy and safety of biologic treatments in familial Mediterranean fever","volume":"346","author":"Akgul","year":"2013","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.smim.2013.10.008_bib1160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2013.03.004","article-title":"Myositis in a patient with familial Mediterranean fever and spondyloarthritis successfully treated with anakinra","author":"Estublier","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.smim.2013.10.008_bib1165","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(04)17401-1","article-title":"Prevention of cold-associated acute inflammation in familail cold autoinflammatory syndrome by interleukin-1 receptor antagonist prevents","volume":"364","author":"Hoffman","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.smim.2013.10.008_bib1170","first-page":"2085","article-title":"Anakinra prevents symptoms of familial cold autoinflammatory syndrome and Raynaud's disease","volume":"33","author":"Metyas","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1175","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/art.20033","article-title":"Spectrum of clinical features in Muckle\u2013Wells syndrome and response to anakinra","volume":"50","author":"Hawkins","year":"2004","journal-title":"Arthr Rheumat"},{"key":"10.1016\/j.smim.2013.10.008_bib1180","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1056\/NEJM200306193482523","article-title":"Interleukin-1 receptor antagonist in the Muckle\u2013Wells syndrome","volume":"348","author":"Hawkins","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.smim.2013.10.008_bib1185","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/ard.2005.038091","article-title":"Hearing improvement in a patient with variant Muckle\u2013Wells syndrome in response to interleukin 1 receptor antagonism","volume":"65","author":"Rynne","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib1190","doi-asserted-by":"crossref","first-page":"R64","DOI":"10.1186\/ar4237","article-title":"Treatment of Muckle\u2013Wells syndrome: analysis of two IL-1-blocking regimens","volume":"15","author":"Kuemmerle-Deschner","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.smim.2013.10.008_bib1195","first-page":"161","article-title":"Muckle\u2013Wells syndrome: a treatable cause of congenital sensorineural hearing loss","volume":"9","author":"Stew","year":"2013","journal-title":"B-ENT"},{"key":"10.1016\/j.smim.2013.10.008_bib1200","doi-asserted-by":"crossref","DOI":"10.1111\/ced.12186","article-title":"Muckle\u2013Wells syndrome without mutation in exon 3 of the NLRP3 gene, identified by evidence of excessive monocyte production of functional interleukin 1beta and rapid response to anakinra","author":"Sabroe","year":"2013","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.smim.2013.10.008_bib1205","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3109\/0886022X.2013.790300","article-title":"Nephrotic syndrome and AA amyloidosis revealing adult-onset cryopyrin-associated periodic syndrome","volume":"35","author":"Enriquez","year":"2013","journal-title":"Renal Fail"},{"key":"10.1016\/j.smim.2013.10.008_bib1210","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/art.30378","article-title":"Role of interleukin-1beta in NLRP12-associated autoinflammatory disorders and resistance to anti-interleukin-1 therapy","volume":"63","author":"Jeru","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.smim.2013.10.008_bib1215","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/art.20953","article-title":"Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease","volume":"52","author":"Lovell","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib1220","doi-asserted-by":"crossref","first-page":"e49408","DOI":"10.1371\/journal.pone.0049408","article-title":"Homeostatic tissue responses in skin biopsies from NOMID patients with constitutive overproduction of IL-1beta","volume":"7","author":"Aubert","year":"2012","journal-title":"PLOS One"},{"key":"10.1016\/j.smim.2013.10.008_bib1225","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/annrheumdis-2012-202082","article-title":"Microarray-based gene expression profiling in patients with cryopyrin-associated periodic syndromes defines a disease-related signature and IL-1-responsive transcripts","volume":"72","author":"Balow","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib1230","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/ar2197","article-title":"Falling into TRAPS-receptor misfolding in the TNF receptor 1-associated periodic fever syndrome","volume":"9","author":"Kimberley","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.smim.2013.10.008_bib1235","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1136\/annrheumdis-2012-202087","article-title":"Anakinra for a refractory case of intermittent hydrarthrosis with a TRAPS-related gene mutation","volume":"72","author":"Andres","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib1240","doi-asserted-by":"crossref","first-page":"e73443","DOI":"10.1371\/journal.pone.0073443","article-title":"First report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS)","volume":"8","author":"Lucherini","year":"2013","journal-title":"PLOS One"},{"key":"10.1016\/j.smim.2013.10.008_bib1245","doi-asserted-by":"crossref","first-page":"R86","DOI":"10.1152\/ajpregu.00504.2006","article-title":"Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes","volume":"292","author":"Simon","year":"2007","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.smim.2013.10.008_bib1250","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1365-2133.2009.09404.x","article-title":"Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra","volume":"161","author":"Brenner","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1255","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/rheumatology\/keh479","article-title":"Anakinra for flares of pyogenic arthritis in PAPA syndrome","volume":"44","author":"Dierselhuis","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.smim.2013.10.008_bib1260","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/ard.2009.126185","article-title":"Variable expression and treatment of PAPA syndrome","volume":"70","author":"Schellevis","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib1265","doi-asserted-by":"crossref","first-page":"13501","DOI":"10.1073\/pnas.2135380100","article-title":"Pyrin binds the PSTPIP1\/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway","volume":"100","author":"Shoham","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.smim.2013.10.008_bib1270","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1002\/art.34332","article-title":"Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne)","volume":"64","author":"Demidowich","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib1275","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12016-012-8351-x","article-title":"Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet's syndrome: a comprehensive review and disease classification criteria","volume":"45","author":"Marzano","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.smim.2013.10.008_bib1280","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/INF.0b013e3182700cc1","article-title":"Chronic recurrent multifocal osteomyelitis and deficiency of interleukin-1-receptor antagonist","volume":"32","author":"Sakran","year":"2013","journal-title":"Pediatric Infect Dis J"},{"key":"10.1016\/j.smim.2013.10.008_bib1285","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1002\/art.22966","article-title":"NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort","volume":"56","author":"Arostegui","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib1290","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.berh.2011.10.017","article-title":"Miscellaneous non-inflammatory musculoskeletal conditions, Blau syndrome","volume":"25","author":"Punzi","year":"2011","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1295","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1542\/peds.2010-2192","article-title":"Clinical, genetic, and therapeutic diversity in 2 patients with severe mevalonate kinase deficiency","volume":"129","author":"Ruiz Gomez","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.smim.2013.10.008_bib1300","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1136\/annrheumdis-2012-201818","article-title":"Efficacy of anti-IL-1 treatment in Majeed syndrome","volume":"72","author":"Herlin","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib1305","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1136\/annrheumdis-2012-201818","article-title":"Efficacy of anti-IL-1 treatment in Majeed syndrome","volume":"72","author":"Herlin","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib1310","first-page":"1140","article-title":"Schnitzler syndrome\u2014report on a fourteen-year course of the disease and an overview of information on the disease","volume":"54","author":"Adam","year":"2008","journal-title":"Vnitr Lek"},{"key":"10.1016\/j.smim.2013.10.008_bib1315","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1177\/039463201002300226","article-title":"Successful treatment of Schnitzler's syndrome with anakinra after failure of rituximab trial","volume":"23","author":"Cascavilla","year":"2010","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.smim.2013.10.008_bib1320","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaad.2007.03.036","article-title":"Schnitzler syndrome: treatment failure to rituximab but response to anakinra","volume":"57","author":"Eiling","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1325","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3109\/03009742.2010.493894","article-title":"Treatment of Schnitzler's syndrome with anakinra: report of three cases and review of the literature","volume":"40","author":"Gran","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1330","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1750-1172-5-38","article-title":"The Schnitzler syndrome","volume":"5","author":"Lipsker D","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib1335","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/j.1365-4632.2009.04151.x","article-title":"Schnitzler syndrome: response to anakinra in two cases and a review of the literature","volume":"48","author":"Schuster","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1340","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10067-011-1804-4","article-title":"Schnitzler's syndrome associated with pancreatitis: a disease of IL-1 dysregulation","volume":"31","author":"Larocca","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1345","first-page":"427","article-title":"Schnitzler's syndrome: a case report and literature review of the response to treatment with anakinra","volume":"140","author":"Benitez Gutierrez","year":"2013","journal-title":"Med Clin"},{"key":"10.1016\/j.smim.2013.10.008_bib1350","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3324\/haematol.2013.084830","article-title":"Schnitzler syndrome\u2014an under diagnosed clinical entity","volume":"98","author":"Jain","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.smim.2013.10.008_bib1355","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/all.12129","article-title":"Schnitzler's syndrome: diagnosis, treatment, and follow-up","volume":"68","author":"Simon","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.smim.2013.10.008_bib1360","doi-asserted-by":"crossref","first-page":"e59327","DOI":"10.1371\/journal.pone.0059327","article-title":"Effect of in vitro and in vivo anakinra on cytokines production in Schnitzler syndrome","volume":"8","author":"Launay","year":"2013","journal-title":"PLOS One"},{"key":"10.1016\/j.smim.2013.10.008_bib1365","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2340\/00015555-1307","article-title":"Dermal interleukin-1 expression and effective and long-lasting therapy with interleukin-1 receptor antagonist anakinra in Schnitzler syndrome","volume":"92","author":"Volz","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.smim.2013.10.008_bib1370","doi-asserted-by":"crossref","DOI":"10.1007\/s10792-013-9788-5","article-title":"Current and future treatments for Behcet's uveitis: road to remission","author":"Mesquida","year":"2013","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.smim.2013.10.008_bib1375","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/archderm.142.12.1591","article-title":"Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1\/NALP3 mutations","volume":"142","author":"Leslie","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1380","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1546-0096-9-21","article-title":"Partial response to anakinra in life-threatening Henoch\u2013Schonlein purpura: case report","volume":"9","author":"Boyer","year":"2011","journal-title":"Pediatr Rheumatol Online J"},{"issue":"Suppl.","key":"10.1016\/j.smim.2013.10.008_bib1385","first-page":"S536","article-title":"Functional outcomes of treatment of neonatal onset multisystem inflammatory disease (NOMID) with anakina","volume":"52","author":"Paul","year":"2005","journal-title":"Arthr Rheumat"},{"key":"10.1016\/j.smim.2013.10.008_bib1390","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib1395","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/acr.21625","article-title":"Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis","volume":"64","author":"Dewitt","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"Suppl. 1","key":"10.1016\/j.smim.2013.10.008_bib1400","first-page":"265","article-title":"Prompt response to treatment with anakinra in adult onset Still's disease","volume":"63","author":"Aelion","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.smim.2013.10.008_bib1405","first-page":"263","article-title":"Anakinra in the treatment of adult onset Still's disease","volume":"63","author":"Haraoui","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib1410","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1111\/j.1756-185X.2010.01474.x","article-title":"A case of refractory adult-onset Still's disease treated with anakinra","volume":"13","author":"Lahiri","year":"2010","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib1415","doi-asserted-by":"crossref","first-page":"R91","DOI":"10.1186\/ar3366","article-title":"Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study","volume":"13","author":"Laskari","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.smim.2013.10.008_bib1420","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s10067-010-1459-6","article-title":"May anakinra be used earlier in adult onset Still disease?","volume":"29","author":"Moulis","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1425","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10067-007-0791-y","article-title":"Acute hepatitis in adult Still's disease during corticosteroid treatment successfully treated with anakinra","volume":"27","author":"Mylona","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1430","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jbspin.2010.09.014","article-title":"Adult-onset Still's disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra","volume":"78","author":"Raffeiner","year":"2011","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.smim.2013.10.008_bib1435","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/01.rhu.0000089966.48691.7f","article-title":"Successful treatment of a patient with refractory adult-onset Still's disease with anakinra","volume":"9","author":"Rudinskaya","year":"2003","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1440","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3109\/s10165-009-0254-1","article-title":"Marked effect and steroid-sparing ability of anakinra on a patient with refractory adult-onset Still's disease","volume":"20","author":"Tamaki","year":"2010","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1445","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/ard.2004.026617","article-title":"Refractory adult onset Still's disease successfully treated with anakinra","volume":"64","author":"Vasques Godinho","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib1450","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1136\/ard.2008.093492","article-title":"Continuation of anakinra despite the development of a pruritic rash in an otherwise refractory case of adult-onset Still's disease","volume":"68","author":"Vordenbaumen","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib1455","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.3899\/jrheum.080150","article-title":"Blockade of interleukin 1 receptor in Still's disease affects activation of peripheral T-lymphocytes","volume":"35","author":"Youssef","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1460","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/ard.2007.082859","article-title":"Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease","volume":"67","author":"Woo","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib1465","first-page":"681","article-title":"Adult-onset Still's disease with liver failure requiring liver transplantation","volume":"32","author":"Teran","year":"2009","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1470","first-page":"423","article-title":"A rare case of arthritis and fever","volume":"68","author":"Rinkin","year":"2013","journal-title":"Rev Med Liege"},{"key":"10.1016\/j.smim.2013.10.008_bib1475","first-page":"47","article-title":"Adult-onset Still's disease: clinical, serological and therapeutic considerations","volume":"31","author":"Iliou","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1480","doi-asserted-by":"crossref","first-page":"349521","DOI":"10.1155\/2012\/349521","article-title":"Adult-onset Still's disease masquerading as sepsis in an asplenic active duty soldier","volume":"2012","author":"Jaqua","year":"2012","journal-title":"Case Rep Med"},{"key":"10.1016\/j.smim.2013.10.008_bib1485","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/acr.21901","article-title":"Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy","volume":"65","author":"Giampietro","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.smim.2013.10.008_bib1490","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3899\/jrheum.091046","article-title":"Macrophage activation syndrome treated with anakinra","volume":"37","author":"Durand","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1495","first-page":"2081","article-title":"Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis","volume":"33","author":"Behrens","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1500","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/RHU.0b013e318205092d","article-title":"Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids","volume":"17","author":"Bruck","year":"2011","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1505","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1529-8019.2010.01339.x","article-title":"Cytophagic histiocytic panniculitis and hemophagocytic lymphohistiocytosis: an overview","volume":"23","author":"Aronson","year":"2010","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.smim.2013.10.008_bib1510","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/acr.20024","article-title":"A 36-year-old woman with recurrent high-grade fevers, hypotension, and hypertriglyceridemia","volume":"62","author":"Chou","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.smim.2013.10.008_bib1515","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/ncprheum0919","article-title":"A case of macrophage activation syndrome successfully treated with anakinra","volume":"4","author":"Kelly","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1520","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/imj.12002","article-title":"Successful treatment of macrophage activation syndrome complicating adult Still disease with anakinra","volume":"42","author":"Loh","year":"2012","journal-title":"Int Med J"},{"key":"10.1016\/j.smim.2013.10.008_bib1525","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3899\/jrheum.121098","article-title":"Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome","volume":"40","author":"Kahn","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1530","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/INF.0b013e31828df4d1","article-title":"Successful immunotherapy in life-threatening parvovirus B19 infection in a child","volume":"32","author":"Butin","year":"2013","journal-title":"Pediatric Infect Dis J"},{"key":"10.1016\/j.smim.2013.10.008_bib1535","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/gene.2012.3","article-title":"Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment","volume":"13","author":"Ravelli","year":"2012","journal-title":"Genes Immun"},{"key":"10.1016\/j.smim.2013.10.008_bib1540","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/ard.2006.068254","article-title":"Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome","volume":"67","author":"Delluc","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib1545","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000326112","article-title":"Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret(R)) in a case of refractory Sweet's syndrome","volume":"222","author":"Kluger","year":"2011","journal-title":"Dermatology"},{"key":"10.1016\/j.smim.2013.10.008_bib1550","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/jamadermatol.2013.2705","article-title":"Neutrophilic urticaria with systemic inflammation: a case series","volume":"149","author":"Belani","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1555","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1159\/000280436","article-title":"Anakinra for difficult-to-treat neutrophilic panniculitis: IL-1 blockade as a promising treatment option for neutrophil-mediated inflammatory skin disease","volume":"220","author":"Lipsker","year":"2010","journal-title":"Dermatology"},{"key":"10.1016\/j.smim.2013.10.008_bib1560","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1182\/blood-2010-04-279240","article-title":"Rationale and efficacy of interleukin-1 targeting in Erdheim\u2013Chester disease","volume":"116","author":"Aouba","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.smim.2013.10.008_bib1565","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2013.06.013","article-title":"Successful treatment of Erdheim\u2013Chester disease by interleukin-1 receptor antagonist protein","author":"Courcoul","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.smim.2013.10.008_bib1570","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jbspin.2012.07.005","article-title":"Favorable radiological outcome of skeletal Erdheim\u2013Chester disease involvement with anakinra","volume":"80","author":"Aubert","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.smim.2013.10.008_bib1575","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/annrheumdis-2011-200743","article-title":"Anakinra treatment of SAPHO syndrome: short-term results of an open study","volume":"71","author":"Wendling","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib1580","doi-asserted-by":"crossref","first-page":"7148","DOI":"10.1073\/pnas.1103681108","article-title":"Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade","volume":"108","author":"Stojanov","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.smim.2013.10.008_bib1585","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1007\/s00296-010-1512-4","article-title":"Typical and severe tumor necrosis factor receptor-associated periodic syndrome in the absence of mutations in the TNFRSF1A gene: a case series","volume":"32","author":"Cantarini","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.smim.2013.10.008_bib1590","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/MPH.0b013e31818ab31f","article-title":"IL-1RA agonist (anakinra) in the treatment of multifocal Castleman disease","volume":"30","author":"Galeotti","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.smim.2013.10.008_bib1595","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00296-009-1169-z","article-title":"Jessner-Kanof disease induced by leflunomide: a dermal variant of cutaneous lupus?","volume":"31","author":"Sparsa","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.smim.2013.10.008_bib1600","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1136\/annrheumdis-2012-201658","article-title":"A child with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation","volume":"71","author":"Cohen","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib1605","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/clpt.2012.69","article-title":"Longitudinal model-based meta-analysis in rheumatoid arthritis: an application toward model-based drug development","volume":"92","author":"Demin","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.smim.2013.10.008_bib1610","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2013.07.003","article-title":"Impact of interleukin-1beta antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial","author":"Hensen","year":"2013","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.smim.2013.10.008_bib1615","doi-asserted-by":"crossref","DOI":"10.1111\/j.1463-1326.2012.01637.x","article-title":"Effect of anti-IL-1beta antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial","author":"Rissanen","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.smim.2013.10.008_bib1620","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.smim.2013.10.008_bib1625","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib1630","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/rheumatology\/kes021","article-title":"Canakinumab induces remission in a patient with resistant familial Mediterranean fever","volume":"51","author":"Hacihamdioglu","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.smim.2013.10.008_bib1635","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1136\/ard.2010.146878","article-title":"The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis","volume":"70","author":"Mitroulis","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib1640","doi-asserted-by":"crossref","first-page":"907","DOI":"10.7326\/0003-4819-156-12-201206190-00027","article-title":"Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab","volume":"156","author":"Brizi","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.smim.2013.10.008_bib1645","first-page":"S115","article-title":"Successful use of canakinumab in a patient with resistant Behcet's disease","volume":"30","author":"Cantarini","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1650","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1136\/annrheumdis-2012-201383","article-title":"Canakinumab in a patient with juvenile Behcet's syndrome with refractory eye disease","volume":"71","author":"Ugurlu","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib1655","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1186\/ar4184","article-title":"The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age","volume":"15","author":"Caorsi","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.smim.2013.10.008_bib1660","first-page":"302","article-title":"Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results)","volume":"31","author":"Imagawa","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1665","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00431-003-1223-x","article-title":"Familial mediterranean fever: revisiting an ancient disease","volume":"162","author":"Ozen","year":"2003","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.smim.2013.10.008_bib1670","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1136\/annrheumdis-2012-202192","article-title":"Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome","volume":"72","author":"de Koning","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib1675","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.semarthrit.2012.06.003","article-title":"Canakinumab in Schnitzler syndrome","volume":"42","author":"Vanderschueren","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib1680","author":"Kolly","year":"2009","journal-title":"Inflammatory role of ASC."},{"key":"10.1016\/j.smim.2013.10.008_bib1685","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1093\/rheumatology\/kes097","article-title":"Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency","volume":"51","author":"Galeotti","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.smim.2013.10.008_bib1690","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/2013.jamadermatol.717","article-title":"Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment","volume":"149","author":"Geusau","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1695","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.37776","article-title":"Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis","volume":"65","author":"Simonini","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib1700","first-page":"795027","article-title":"A case of hyperimmunoglobulinemia d syndrome successfully treated with canakinumab","volume":"2013","author":"Tsitsami","year":"2013","journal-title":"Case Rep Rheumatol"},{"key":"10.1016\/j.smim.2013.10.008_bib1705","first-page":"733","article-title":"Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap)","volume":"2","author":"Church","year":"2008","journal-title":"Biologics: Targets Ther"},{"key":"10.1016\/j.smim.2013.10.008_bib1710","first-page":"1","article-title":"Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS)","volume":"3","author":"Gillespie","year":"2010","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.smim.2013.10.008_bib1715","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1002\/art.23620","article-title":"A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome","volume":"58","author":"Goldbach-Mansky","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib1720","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/0003-4819-157-8-201210160-00003","article-title":"Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial","volume":"157","author":"Hashkes","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.smim.2013.10.008_bib1725","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.clinthera.2012.09.009","article-title":"Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study","volume":"34","author":"Hoffman","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.smim.2013.10.008_bib1730","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1517\/14712590902875518","article-title":"Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS)","volume":"9","author":"Hoffman","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.smim.2013.10.008_bib1735","first-page":"138","article-title":"Rilonacept (arcalyst), an interleukin-1 trap for the treatment of cryopyrin-associated periodic syndromes","volume":"34","author":"Kapur","year":"2009","journal-title":"Pharm Ther"},{"key":"10.1016\/j.smim.2013.10.008_bib1740","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1398-9995.2012.02843.x","article-title":"Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study","volume":"67","author":"Krause","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.smim.2013.10.008_bib1745","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/art.38042","article-title":"Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis","volume":"65","author":"Lovell","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.smim.2013.10.008_bib1750","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/rheumatology\/ket114","article-title":"Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial","volume":"52","author":"Mitha","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.smim.2013.10.008_bib1755","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/acr.21690","article-title":"Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study","volume":"64","author":"Schumacher","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.smim.2013.10.008_bib1760","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/ar4159","article-title":"Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator","volume":"15","author":"Terkeltaub","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.smim.2013.10.008_bib1765","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1136\/annrheumdis-2012-201409","article-title":"IL-1 Trap rilonacept in refractory adult onset Still's disease","volume":"71","author":"Petryna","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.smim.2013.10.008_bib1770","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nm1603","article-title":"Identification of a key pathway required for the sterile inflammatory response triggered by dying cells","volume":"13","author":"Chen","year":"2007","journal-title":"Nat Med"}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532313000894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532313000894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T04:19:48Z","timestamp":1716178788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532313000894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":354,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S1044532313000894"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2013.10.008","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treating inflammation by blocking interleukin-1 in humans","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2013.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}